Skip to main content

PAPEL DE LAS MAP2K MKK3 Y MKK6 EN CANCER Y SU TERAPIA: ESTUDIOS IN VITRO E IN VIVO

SAF2015-64215-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre UNIVERSIDAD DE CASTILLA-LA MANCHA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

VHL promotes immune response against renal cell carcinoma via NF-κB–dependent regulation of VCAM-1

  • Labrousse-Arias, David
  • Martínez-Alonso, Emma
  • Corral-Escariz, María
  • Bienes-Martínez, Raquel
  • Berridy, Jaime
  • Serrano-Oviedo, Leticia
  • Conde, Elisa
  • García-Bermejo, María Laura
  • Giménez-Bachs, José M.
  • Salinas-Sánchez, Antonio S.
  • Sánchez-Prieto, Ricardo
  • Yao, Masahiro
  • Lasa, Marina
  • Calzada, María José
Vascular cell adhesion molecule 1 (VCAM-1) is an adhesion molecule assigned to the activated endothelium mediating immune cells adhesion and extravasation. However, its expression in renal carcinomas inversely correlates with tumor malignancy. Our experiments in clear cell renal cell carcinoma (ccRCC) cell lines demonstrated that von Hippel Lindau (VHL) loss, hypoxia, or PHD (for prolyl hydroxylase domain–containing proteins) inactivation decreased VCAM-1 levels through a transcriptional mechanism that was independent of the hypoxia-inducible factor and dependent on the nuclear factor κB signaling pathway. Conversely, VHL expression leads to high VCAM-1 levels in ccRCC, which in turn leads to better outcomes, possibly by favoring antitumor immunity through VCAM-1 interaction with the α4β1 integrin expressed in immune cells. Remarkably, in ccRCC human samples with VHL nonmissense mutations, we observed a negative correlation between VCAM-1 levels and ccRCC stage, microvascular invasion, and symptom presentation, pointing out the clinical value of VCAM-1 levels as a marker of ccRCC progression., This work was supported by grants from the Instituto de Salud Carlos III (co-funded by the European Union and Fondo Europeo de Desarrollo Regional; grants PI16/02166 and PIE13/00041), a grant from Red Cardiovascular (RD12/0042/0065 to M.J. Calzada), and a grant from Ministerio de Economía y competitividad (SAF2015-64215R to R. Sánchez-Prieto)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion

  • Serrano-Oviedo, Leticia
  • Ortega-Muelas, Marta
  • García-Cano, Jesús
  • Valero, María Ll.
  • Cimas, Francisco J.
  • Pascual-Serra, Raquel
  • Fernández-Aroca, Diego M.
  • Roche, Olga
  • Ruiz-Hidalgo, María J.
  • Belandia, Borja
  • Giménez-Bachs, José M.
  • Salinas-Sánchez, Antonio S.
  • Sánchez-Prieto, Ricardo
[Objectives]: To fully clarify the role of Mitogen Activated Protein Kinase in the therapeutic response to Sorafenib in Renal Cell Carcinoma as well as the cell death mechanism associated to this kinase inhibitor, we have evaluated the implication of several Mitogen Activated Protein Kinases in Renal Cell Carcinoma-derived cell lines., [Materials and methods]: An experimental model of Renal Cell Carcinoma-derived cell lines (ACHN and 786-O cells) was evaluated in terms of viability by MTT assay, induction of apoptosis by caspase 3/7 activity, autophagy induction by LC3 lipidation, and p62 degradation and kinase activity using phospho-targeted antibodies. Knock down of ATG5 and ERK5 was performed using lentiviral vector coding specific shRNA., [Results]: Our data discard Extracellular Regulated Kinase 1/2 and 5 as well as p38 Mitogen Activated Protein Kinase pathways as mediators of Sorafenib toxic effect but instead indicate that the inhibitory effect is exerted through the PI3K/Akt signalling pathway. Furthermore, we demonstrate that inhibition of Akt mediates cell death associated to Sorafenib without caspase activation, and this is consistent with the induction of autophagy, as indicated by the use of pharmacological and genetic approaches., [Conclusion]: The present report demonstrates that Sorafenib exerts its toxic effect through the induction of autophagy in an Akt-dependent fashion without the implication of Mitogen Activated Protein Kinase. Therefore, our data discard the use of inhibitors of the RAF-MEK-ERK1/2 signalling pathway in RCC and support the use of pro-autophagic compounds, opening new therapeutic opportunities for Renal Cell Carcinoma., This work was supported by grants from Fundacion Leticia Castillejo Castillo, Ministerio de Economía y Competitividad (SAF2012-30862, SAF2015-64215R) to RSP and MJRH. RSP and MJRH Research Institutes, and the work carried out in their laboratories received support from the European Community through the Regional Development Funding Program (FEDER). OR has a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla La Mancha (UCLM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

HIF1α suppresses tumor cell proliferation through inhibition of aspartate biosynthesis

  • Meléndez-Rodríguez, Florinda
  • Urrutia, Andrés A.
  • Lorendeau, Doriane
  • Rinaldi, Gianmarco
  • Roche, Olga
  • Böğürcü-Seidel, Nuray
  • Ortega-Muelas, Marta
  • Mesa-Ciller, Claudia
  • Turiel, Guillermo
  • Bouthelier, Antonio
  • Hernansanz-Agustín, Pablo
  • Elorza, Ainara
  • Escasany, Elia
  • Yang Li, Qilong Oscar
  • Torres-Capelli, Mar
  • Tello, Daniel
  • Fuertes, Esther
  • Fraga, Enrique
  • Martínez-Ruiz, Antonio
  • Pérez, Belén
  • Giménez-Bachs, José M.
  • Salinas-Sánchez, Antonio S.
  • Acker, Till
  • Sánchez-Prieto, Ricardo
  • Fendt, Sarah-Maria
  • De Bock, Katrien
  • Aragonés, Julián
Cellular aspartate drives cancer cell proliferation, but signaling pathways that rewire aspartate biosynthesis to control cell growth remain largely unknown. Hypoxia-inducible factor-1α (HIF1α) can suppress tumor cell proliferation. Here, we discovered that HIF1α acts as a direct repressor of aspartate biosynthesis involving the suppression of several key aspartate-producing proteins, including cytosolic glutamic-oxaloacetic transaminase-1 (GOT1) and mitochondrial GOT2. Accordingly, HIF1α suppresses aspartate production from both glutamine oxidation as well as the glutamine reductive pathway. Strikingly, the addition of aspartate to the culture medium is sufficient to relieve HIF1α-dependent repression of tumor cell proliferation. Furthermore, these key aspartate-producing players are specifically repressed in VHL-deficient human renal carcinomas, a paradigmatic tumor type in which HIF1α acts as a tumor suppressor, highlighting the in vivo relevance of these findings. In conclusion, we show that HIF1α inhibits cytosolic and mitochondrial aspartate biosynthesis and that this mechanism is the molecular basis for HIF1α tumor suppressor activity., This work was supported by grants from Ministerio de Economia y Competitividad (SAF2016-76815 and SAF2017-90794-REDT) and Fundació La Marató de TV3 (534/C/2016). F.M.-R. is supported by Ministerio de Economia y Competitividad (BES-2014-068618). A.A.U is supported by the CAM “Atracción de Talento” program. D.L. is supported by the VIB-Marie Curie omics program. S.-M.F. acknowledges funding support from a Marie Curie CIG, FWO Odysseus II, FWO Research Grants, Eugène Yourassowsky Schenking, and KU Leuven Methusalem co-funding. O.R. has a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM). R.S.P acknowledges funding support from Ministerio de Educación y Ciencia (SAF2015-64215-R) and Fundacion Leticia Castillejo Castillo. A.M.-R. acknowledges funding support from Ministerio de Economía y Competitividad (PI15/00107)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy

  • Fernández-Aroca, Diego M.
  • Roche, Olga
  • Sabater, Sebastiá
  • Pascual-Serra, Raquel
  • Ortega-Muelas, Marta
  • Sánchez-Pérez, Isabel
  • Belandia, Borja
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
Targeting cell cycle has become one of the major challenges in cancer therapy, being Palbociclib, a CDK4/6 inhibitor, an excellent example. Recently, it has been reported that Palbociclib could be a novel radiosensitizer agent. In an attempt to clarify the molecular basis of this effect we have used cell lines from colorectal (HT29, HCT116) lung (A549, H1299) and breast cancer (MCF-7). Our results indicate that the presence of a p53 wild type is strictly required for Palbociclib to exert its radiosensitizing effect, independently of the inhibitory effect exerted on CDK4/6. In fact, abrogation of p53 in cells with functional p53 blocks the radiosensitizing effect of Palbociclib. Moreover, no radiosensitizing effect is observed in cells with non-functional p53, but restoration of p53 function promotes radiosensitivity associated to Palbociclib. Furthermore, the presence of Palbociclib blocks the transcriptional activity of p53 in an ATM-dependent-fashion after ionizing radiation exposure, as the blockage of p21/WAF1 expression demonstrates. These observations are a proof of concept for a more selective therapy, based on the combination of CDK4/6 inhibition and radiotherapy, which would only benefit to those patients with a functional p53 pathway., This work was supported by grants from Fundación Leticia Castillejo Castillo, and Ministerio de Economía y Competitividad (SAF2015-64215-R) to RSP and MJRH. OR has a contract for accessing the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla-La Mancha and received partial support from the European Social Fund through its Operative Program for Castilla-La Mancha (2007–2013). RSP and MJRH Research Institute, and the work carried out in their laboratory, received partial support from the European Community through the Regional Development Funding Program (FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Erk5 pathway is a new indirect target of sorafenib

  • Ortega-Muelas, Marta
  • Muñoz-Martinez-Blanco, L.
  • Pascual-Serra, Raquel
  • Roche, Olga
  • Fernández-Aroca, Diego M.
  • Olivares-Martin, R.
  • Ruiz-Hidalgo, María J.
  • Belandia, Borja
  • Sánchez-Prieto, Ricardo
Resumen del trabajo presentado al 1st PhD Research Symposium in Health Sciences and Biomedicine, celebrado en la Universidad Autónoma de Madrid el 18 de mayo de 2018., MINECO (SAF2015-64215-R). Fundación Leticia Castillejo., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Evaluación de biomarcadores en carcinoma ductal in situ de mama: expresión inmunohistoquímica y correlación clinicopatológica

  • Sarabia Ochoa, Ignacia Rosalía
Tesis Doctoral realizada en el Departamento de Ciencias Médicas de la Facultad de Medicina de Albacete, para optar al grado de Doctor en Medicina y Cirugía., El carcinoma ductal in situ (CDIS) es una forma no invasiva de cáncer de mama que puede progresar a cáncer invasivo. Es una lesión caracterizada por una heterogeneidad significativa, en términos de morfología, tinción inmunohistoquímica (IHQ), firmas moleculares y expresión clínica. La identificación de los factores que predicen la recidiva local tanto en la forma in situ o como invasiva facilitarían las recomendaciones de tratamiento. Los cambios biológicos en los diversos componentes celulares del CDIS, que incluyen las células epiteliales tumorales, las células mioepiteliales y las células del estroma, pueden ser la clave para determinar si una lesión determinada evolucionará o no a carcinoma invasivo. Para algunos pacientes, la escisión quirúrgica proporciona el tratamiento adecuado, pero un subconjunto de pacientes experimentará la recurrencia de CDIS o la progresión a carcinoma ductal invasivo (CDI)., Financiado por SAF2015-64215 del Ministerio de Ciencia, Innovación y Universidades y Fundación Leticia Castillejo., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Blockage of autophagic flux is associated with lymphocytosis and higher percentage of tumoral cells in chronic lymphocytic leukemia of B cells

  • Romero-Macías, Juan-Ramón
  • Pascual-Serra, Raquel
  • Roche, Olga
  • Ruiz-Marcos, Francisco
  • Serrano-Martínez, Ana
  • González-Aguado, Patricia
  • Belandia, Borja
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
[Purpose]: Autophagy has lately emerged as an important biological process with implications in several hematological pathologies. Recently, a growing body of evidence supports a putative role of autophagy in chronic lymphocytic leukemia; however, no definitive clue has been established so far. To elucidate this issue, we have developed a pilot study to measure autophagic flux in peripheral blood mononuclear cells from chronic lymphocytic leukemia patients, and explored its correlation with classical clinical/analytical parameters., [Methods/patients]: Thirty-three chronic lymphocytic leukemia patients participated in the study. Autophagic flux in peripheral blood mononuclear cells was determined by western blot measuring the levels of the proteins p62 and lipidated LC3. Moreover, p62 mRNA levels were analyzed by RT-qPCR., [Results]: Lymphocytosis and the percentage of tumoral lymphocytes in chronic lymphocytic leukemia patients statistically correlate with a blocked autophagic flux., [Conclusion]: Alterations in autophagic flux could play an important role in the physiopathology of chronic lymphocytic leukemia., This work was supported by Grants from Fundación Leticia Castillejo Castillo, Ministerio de Economía y Competitividad (SAF2012-30862, SAF2015-64215R to RSP and MJRH) and Sociedad Castellano Manchega de Hematología y Hemoterapia (to JRRM). OR has a contract for access to the Spanish System of Science, Technology and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM). RPS has a predoctoral contract for the training of research staff funded by the University of Castilla-La Mancha (UCLM) (2014/10340). RSP and MJRH Research Institutes, and the work carried out in their laboratories received support from the European Community through the Regional Development Funding Program (FEDER).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

E1a is an exogenous in vivo tumour suppressor

  • Cimas, Francisco J.
  • Callejas-Valera, Juan L.
  • García-Olmo, Dolores C.
  • Hernández-Losa, Javier
  • Melgar-Rojas, Pedro
  • Ruiz-Hidalgo, María J.
  • Pascual-Serra, Raquel
  • Ortega-Muelas, Marta
  • Roche, Olga
  • Marcos, Pilar
  • García-Gil, Elena
  • Fernández-Aroca, Diego M.
  • Ramón y Cajal, Santiago
  • Gutkind, J. Silvio
  • Sánchez-Prieto, Ricardo
The E1a gene from adenovirus has become a major tool in cancer research. Since the discovery of E1a, it has been proposed to be an oncogene, becoming a key element in the model of cooperation between oncogenes. However, E1a's in vivo behaviour is consistent with a tumour suppressor gene, due to the block/delay observed in different xenograft models. To clarify this interesting controversy, we have evaluated the effect of the E1a 13s isoform from adenovirus 5 in vivo. Initially, a conventional xenograft approach was performed using previously unreported HCT116 and B16-F10 cells, showing a clear anti-tumour effect regardless of the mouse's immunological background (immunosuppressed/immunocompetent). Next, we engineered a transgenic mouse model in which inducible E1a 13s expression was under the control of cytokeratin 5 to avoid side effects during embryonic development. Our results show that E1a is able to block chemical skin carcinogenesis, showing an anti-tumour effect. The present report demonstrates the in vivo anti-tumour effect of E1a, showing that the in vitro oncogenic role of E1a cannot be extrapolated in vivo, supporting its future use in gene therapy approaches., This work was supported by grants from Fundación Leticia Castillejo Castillo and MINECO (SAF 2015 64215-R) and from JCCM (PPII10-0141-0404) to RSP. F. Cimas was supported by Fundación Leticia Castillejo Castillo and Cátedra Enresa. RSP research institution received support from the European Community through the regional development funding programme (FEDER)., Peer reviewed